Objective -Stereotactic transplantation of bone marrow stromal cells (BMSCs) enables efficient delivery to the infarct brain. This study was aimed to assess its optimal timing and cell dose for ischemic stroke.
be harvested from the patients themselves without ethical issue and can be transplanted without immunological problems. Recent studies have shown that the engrafted BMSCs survive, migrate toward injured tissue, express the proteins specific for the neural cells, and improve neurological function when transplanted into various kinds of animal models of central nervous system (CNS) disorders, including cerebral infarct 1, 2 . Alternatively, the BMSCs are known to rescue the injured neurons by releasing neuroprotective or neurotrophic factors 3, 4 . In fact, preliminary clinical trials of BMSC transplantation for CNS disorders have been already started [5] [6] [7] .
As recently pointed out by several researchers, however, it should be reminded that several problems to be solved still exist to launch its clinical application for CNS disorders. The issues include the optimal route, timing, and dose of donor cell delivery. Although all of them are critical to yield its therapeutic significance, there are few studies that scientifically determine the most favorable protocol even in animal experiments 2, [8] [9] [10] [11] [12] . Very recently, the authors have demonstrated that intracerebral transplantation of 1 x 10 6 of the BMSCs at one week after the onset of permanent middle cerebral artery (MCA) occlusion significantly enhances functional recovery of rats, whereas intravenous administration of 3 x 10 6 of the BMSCs at the same timing does not promote it. In vivo near infrared (NIR) fluorescence imaging could clearly visualize their migration towards cerebral infarct during 4 weeks after transplantation in intracerebral group, but not in intravenous group.
The BMSCs were widely distributed in the ischemic brain and a certain subgroup of them expresses neural cell markers in the intracerebral group, but not in the intravenous group 13 .
Based on these considerations, this study was aimed to clarify the optimal timing and dose of BMSC transplantation for cerebral infarct in rats. For this purpose, 1 x 10 5 or 1 x 10 6 of BMSC were stereotactically transplanted at 1 or 4 weeks after the onset of permanent MCA occlusion. In addition to behavioral test, in vivo NIR fluorescence imaging was employed to track the engrafted cells. Finally, the distribution and phenotypic fate of engrafted cells were evaluated with immunohistochemistry.
MATERIALS AND METHODS

Preparation of BMSC
All animal experiments were approved by the Animal Studies Ethical Committee of the Hokkaido University Graduate School of Medicine. Green fluorescence protein (GFP)-transgenic rats were purchased from Japan SLC, Inc., and Sprague-Dawley (SD) rats were purchased from CLEA Japan, Inc. (n=40). The BMSCs were isolated from 8-week-old GFP rat as described previously 14, 15 .
The cells were passed 3 times for subsequent experiments.
The cultured BMSCs were labeled with QD800 Q-tracker cell labeling kits (CdSeTe/ZnS: T -10 nm core-shell type, 5-10 nm polymer coating; Invitrogen, Hayward, CA, USA), as described before 13, 15 . The cells were incubated at 37 ℃ for 15 hr and were washed 3 times in phosphate-buffered saline (PBS) before transplantation.
Permanent MCA Occlusion Model
A focal cerebral infarct was induced by permanent occlusion of the right middle cerebral artery (MCA) with 1-hr occlusion of the bilateral common carotid arteries (CCAs), as described before [13] [14] [15] [16] .
Briefly, the 8-week-old male SD rats were anesthetized, and the bilateral CCA were exposed through a ventral midline incision of the cervical portion. Then, a 1.5-cm vertical skin incision was performed between the right eye and ear. The temporal muscle was scraped from temporal bone, and a 7 x 7 mm temporal craniotomy was performed, using a small dental drill. The dura mater was carefully kept intact. and the right MCA was ligated using 10-0 nylon thread through the dura mater. Then, the craniotomy was closed with the temporal bone flap. The temporal muscle and skin were sutured with 4-0 nylon threads. Subsequently, the bilateral CCAs were occluded by surgical microclips for 1 hr. Only animals that circled towards the paretic side after surgery were included in this study 17 .
BMSC Transplantation
The QD800-labeled BMSCs or PBS were transplanted into the ipsilateral striatum at 1 or 4 weeks after the onset of ischemia, as described previously [13] [14] [15] [16] . The number of transplanted cells was 1 x 10 5 or 1 x 10 6 (n=8 in each group). Briefly, the animals were anesthetized and were fixed to a stereotactic apparatus. The skull was exposed and a burr hole was made 3 mm right to the bregma, using a small dental drill. A Hamilton syringe was inserted 6 mm into the brain parenchyma from the surface of the dura mater, and 10 µl of cell suspension or vehicle was introduced into the striatum over a period of 5 min, using an automatic microinjection pump.
Assessment of Motor Function
Motor function of the animals was semi-quantitatively assessed before and after the onset of ischemia, using a rotarod treadmill (Model MK-630; Muromachi Kikai Co.). The rotarod was set to the acceleration mode of 4 to 40 rpm for 3 min, as described previously . The two best values of four trials in each animal were used to represent performance. The data were expressed as the percentages of those before the onset of ischemia [13] [14] [15] [16] .
In vivo NIR Fluorescence Imaging
The engrafted QD800-labeled cells were visualized at 3 weeks post-transplantation, using in vivo NIR fluorescence imaging, as described previously 13, 15, 18 . Briefly, the animals were anesthetized and were transferred to the chamber of the IVIS 200 Imaging System (Xenogen Co., Alameda, CA, USA). The fluorescence emitted from QD800 was detected through the scalp and the skull, using an 800-nm emission filter and a 710-nm excitation filter. Exposure time was set to 5 seconds. On captured images, the regions of interest (ROIs) were placed on the right parietal area (ROI-1) and on the contralateral parietal area as the reference (ROI-2). Signal intensity in each ROI was expressed in the units of total efficiency (TE) defined as total efficiency (%) = total emission light (photons/seconds) / total excitation light (photons/seconds). The target-to-normal ratio (TNR) was determined by calculating the ratio of TEROI-1/TEROI-2.
Histological Analysis
At 8 weeks after the onset of ischemia, the animals were deeply anesthetized and transcardially perfused, as described previously [13] [14] [15] [16] . The brain was removed, immersed in 4 % paraformaldehyde for two days and embedded in paraffin. The 4-µm-thick coronal sections were prepared for subsequent analysis. To determine the distribution and phenotypic fate of engrafted BMSC, double fluorescence immunohistochemistry was performed, as described previously [19] [20] [21] [22] .
Each section was treated with the mouse monoclonal antibody against GFAP (dilution 1:500; BD .
Statistical Analysis
All data were expressed as mean ± standard deviation. Continuous data were compared, using oneor two-factor ANOVA followed by Scheffe's post-hoc test among more than 3 groups. Values of P<0.05 were considered statistically significant.
RESULTS
Timing and Dose of BMSC Transplantation Affect Functional Recovery
All animals survived throughout the experiment and were used for subsequent analysis. As shown in Fig. 1 , all animals showed severe neurological deficit during 1 week after the onset of ischemia.
There was no significant difference in motor deficits among the groups at 7 days post-ischemia.
When the BMSCs were stereotactically transplanted at 1 week post-ischemia, both 1 x 10 5 (P<0.05) and 1 x 10 6 of them (P<0.05) significantly enhanced the recovery of motor function at 4 weeks post-transplantation (Fig. 1A) . On the other hands, there were no significant differences in motor deficits during 4 weeks post-ischemia among the animals that were treated with BMSCs or vehicle at 4 weeks post-ischemia. However, only the animals treated with 1 x 10 6 of BMSCs showed significant recovery of motor function after transplantation (P<0.05, Fig. 1B ).
In vivo NIR Fluorescence Imaging
In vivo NIR fluorescence imaging was performed to track the QD800-labeled BMSCs at 3 weeks post-transplantation. The fluorescence emitted from QD800 could clearly be observed in the right respectively. Therefore, the intensity of NIR fluorescence was the most prominent in the peri-infarct area when 1 x 10 6 of BMSCs were transplanted at 1 week post-ischemia (Fig. 2 ).
Engraftment and Differentiation of BMSCs
The distribution of GFP-positive cells was evaluated at 8 weeks post-ischemia. 
DISCUSSION
The present study clearly shows that the timing and dose of stereotactic BMSC transplantation are critical factors to determine the therapeutic effects for ischemic stroke. Thus, there is no significant difference in functional recovery between 1 x 10 5 group and 1 x 10 6 group when the BMSCs are transplanted at one week after the onset, although in vitro optical imaging and histological analysis demonstrate that their distribution in the peri-infarct area differs between two groups. On the other hands, 1 x 10 6 , but not 1 x 10 5 , of BMSC significantly promote functional recovery when transplanted at 4 weeks after the onset. In vitro optical imaging and histological analysis also reveal that their distribution in the peri-infarct area is proportional to their therapeutic effects.
Therefore, these findings strongly suggest that optimal timing and dose should precisely be evaluated when establishing the treatment protocol of BMSC transplantation for ischemic stroke.
Unresolved Issues in Cell Therapy for Ischemic Stroke
As aforementioned, some investigators have already started preliminary clinical trials of BMSC transplantation for ischemic stroke. Thus, Bang et al. intravenously injected the autologous BMSC into 5 patients with severe neurological deficits due to ischemic stroke at 5 to 9 weeks after the onset, and concluded that autologous BMSC infusion is a feasible and safe therapy that may improve functional recovery 5 .
Optimal Timing and Dose of Cell Therapy for Ischemic Stroke
In the majority of animal studies, the BMSCs are transplanted within 24 hours or 7 days after the onset of cerebral ischemia, whereas they are usually transplanted several weeks (or even several months) after the onset in clinical situation [5] [6] [7] . Therefore, a considerable gap of treatment protocol exists between animal experiments and clinical trials, which may correspond to "inadequate preclinical testing" on neuroprotective agents 24 . The difficulty to rapidly expand the autologous BMSCs may largely explain this "delay" of cell therapy for patients with ischemic stroke. Considering these observations, this study is the first direct evaluation of how number of transplanted BMSCs and the timing of stereotactic transplantation after ischemic stroke affect the therapeutic benefits. Thus, stereotactic transplantation therapy may require a smaller number of BMSCs to yield significant beneficial effects in early phase (within 7 days) of ischemia. However, a larger number of BMSCs would be crucial to achieve same therapeutic effects in late phase (around 4 weeks) of ischemia.
As aforementioned, the BMSCs are considered to promote functional recovery after ischemic stroke through multiple mechanisms 3 . A certain subpopulation of BMSCs may directly differentiate into the neural cells and replace the lost neural tissue 33, 34 . They can alter their gene expression profile in response to the surrounding microenvironment and differentiate into the neurons without evidence of cell fusion 3, 35 . Alternatively, the BMSCs may support the survival of host neurons by releasing the neuroprotective or neurotrophic factors, including nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). This speculation is quite natural because the 
CONCLUSIONS
The present findings strongly suggest the importance of optimal timing and cell dose to yield therapeutic effects of BMSC transplantation for ischemic stroke. First, a therapeutic time window for stereotactic BMSC transplantation at least ranges from one to four weeks after the onset of ischemic stroke. Second, optimal number of BMSCs may differ in the treatment period. Earlier transplantation requires a smaller number of donor cells for beneficial effects. 
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